Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology - PubMed (original) (raw)

Review

Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology

Alexander Khoruts et al. Nat Rev Gastroenterol Hepatol. 2021 Jan.

Abstract

Faecal microbiota transplantation (FMT) has emerged as a remarkably successful treatment for recurrent Clostridioides difficile infection that cannot be cured with antibiotics alone. Understanding the complex biology and pathogenesis of C. difficile infection, which we discuss in this Perspective, is essential for understanding the potential mechanisms by which FMT cures this disease. Although FMT has already entered clinical practice, different microbiota-based products are currently in clinical trials and are vying for regulatory approval. However, all these therapeutics belong to an entirely new class of agents that require the development of a new branch of pharmacology. Characterization of microbiota therapeutics uses novel and rapidly evolving technologies and requires incorporation of microbial ecology concepts. Here, we consider FMT within a pharmacological framework, including its essential elements: formulation, pharmacokinetics and pharmacodynamics. From this viewpoint, multiple gaps in knowledge become apparent, identifying areas that require systematic research. This knowledge is needed to help clinical providers use microbiota therapeutics appropriately and to facilitate development of next-generation microbiota products with improved safety and efficacy. The discussion here is limited to FMT as a representative of microbiota therapeutics and recurrent C. difficile as the indication; however, consideration of the intrinsic basic principles is relevant to this entire class of microbiota-based therapeutics.

PubMed Disclaimer

Similar articles

• Fecal Microbiota Transplantation Increases Colonic IL-25 and Dampens Tissue Inflammation in Patients with Recurrent Clostridioides difficile.
  Jan N, Hays RA, Oakland DN, Kumar P, Ramakrishnan G, Behm BW, Petri WA Jr, Marie C. Jan N, et al. mSphere. 2021 Oct 27;6(5):e0066921. doi: 10.1128/mSphere.00669-21. Epub 2021 Oct 27. mSphere. 2021. PMID: 34704776 Free PMC article.
• An ecological framework to understand the efficacy of fecal microbiota transplantation.
  Xiao Y, Angulo MT, Lao S, Weiss ST, Liu YY. Xiao Y, et al. Nat Commun. 2020 Jul 3;11(1):3329. doi: 10.1038/s41467-020-17180-x. Nat Commun. 2020. PMID: 32620839 Free PMC article.
• Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent Clostridioides difficile infection.
  McMillan AS, Zhang G, Dougherty MK, McGill SK, Gulati AS, Baker ES, Theriot CM. McMillan AS, et al. mSphere. 2024 Oct 29;9(10):e0070624. doi: 10.1128/msphere.00706-24. Epub 2024 Oct 8. mSphere. 2024. PMID: 39377587 Free PMC article.
• Fecal Microbiota Transplantation and Microbial Therapeutics for the Treatment of Clostridioides difficile Infection in Pediatric Patients.
  Bernard R, Hourigan SK, Nicholson MR. Bernard R, et al. J Pediatric Infect Dis Soc. 2021 Nov 17;10(Supplement_3):S58-S63. doi: 10.1093/jpids/piab056. J Pediatric Infect Dis Soc. 2021. PMID: 34791396 Free PMC article. Review.
• Understanding the mechanisms of faecal microbiota transplantation.
  Khoruts A, Sadowsky MJ. Khoruts A, et al. Nat Rev Gastroenterol Hepatol. 2016 Sep;13(9):508-16. doi: 10.1038/nrgastro.2016.98. Epub 2016 Jun 22. Nat Rev Gastroenterol Hepatol. 2016. PMID: 27329806 Free PMC article. Review.

Cited by

• The evaluation of fecal microbiota transplantation vs vancomycin in a Clostridioides difficile infection model.
  Xu Q, Zhang S, Quan J, Wu Z, Gu S, Chen Y, Zheng B, Lv L, Li L. Xu Q, et al. Appl Microbiol Biotechnol. 2022 Oct;106(19-20):6689-6700. doi: 10.1007/s00253-022-12154-z. Epub 2022 Sep 10. Appl Microbiol Biotechnol. 2022. PMID: 36085529
• [Research progress on the relationship between gut microbiota dysbiosis and osteoarthritis].
  Jiang S, Shen B. Jiang S, et al. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2023 Mar 15;37(3):371-376. doi: 10.7507/1002-1892.202212037. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2023. PMID: 36940999 Free PMC article. Review. Chinese.
• Domestic Environment and Gut Microbiota: Lessons from Pet Dogs.
  Hernandez J, Rhimi S, Kriaa A, Mariaule V, Boudaya H, Drut A, Jablaoui A, Mkaouar H, Saidi A, Biourge V, Borgi MA, Rhimi M, Maguin E. Hernandez J, et al. Microorganisms. 2022 Apr 30;10(5):949. doi: 10.3390/microorganisms10050949. Microorganisms. 2022. PMID: 35630391 Free PMC article. Review.
• History of fecal transplantation; camel feces contains limited amounts of Bacillus subtilis spores and likely has no traditional role in the treatment of dysentery.
  Koopman N, van Leeuwen P, Brul S, Seppen J. Koopman N, et al. PLoS One. 2022 Aug 10;17(8):e0272607. doi: 10.1371/journal.pone.0272607. eCollection 2022. PLoS One. 2022. PMID: 35947590 Free PMC article. Review.

References

1. 1. Costello, E. K., Stagaman, K., Dethlefsen, L., Bohannan, B. J. & Relman, D. A. The application of ecological theory toward an understanding of the human microbiome. Science 336, 1255–1262 (2012). - PubMed - PMC
2. 1. Adams, J. B. et al. Microbiota transplant therapy and autism: lessons for the clinic. Expert. Rev. Gastroenterol. Hepatol. 13, 1033–1037 (2019). - PubMed
3. 1. Dutta, S. K. et al. Parkinson’s disease: the emerging role of gut dysbiosis, antibiotics, probiotics, and fecal microbiota transplantation. J. Neurogastroenterol. Motil. 25, 363–376 (2019). - PubMed - PMC
4. 1. Oren, A. & Rupnik, M. Clostridium difficile and Clostridioides difficile: two validly published and correct names. Anaerobe 52, 125–126 (2018). - PubMed
5. 1. Drekonja, D. et al. Fecal microbiota transplantation for Clostridium difficile infection: a systematic review. Ann. Intern. Med. 162, 630–638 (2015). - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database